• 8:30 - 18:00 M-T / 8.30 - 15.00 F

COVICEL

Print

“CLINICAL STUDY PHASE 1/2 FOR ASSESSING THE SAFETY AND EFFECTIVENESS OF THE CELLULAR PRODUCT HC016 IN PATIENTS WITH ACUTE RESPIRATORY DISTRESS CAUSED BY COVID-19”

Call identifier: COVID-19

Reference Nº: CO-2020/00003

Project financed by the Department of Economic Development and Infrastructures of the Basque Government.

Histocell has been involved in contributing its knowledge and experience in finding solutions to face the health emergency of COVID-19 through a cell therapy drug. The HC016 treatment is based on preconditioned adipose tissue mesenchymal stem cells for critically ill patients who are in the Intensive Care Unit and who have Acute Respiratory Distress Syndrome (ARDS), the most serious complication of COVID-19 infection.

Thus, the objective of the project is to carry out the phase 1/2 clinical study of the HC016 cell therapy drug in patients with ARDS caused by COVID-19. It is intended to reduce lung inflammation and overcome the situation of ARDS, prevent the establishment of irreversible damage to the alveolar tissue and, therefore, improve the clinical situation and the quality of life of the patient.

Histocell Headquarters

Parque Tecnológico 801A, 2º
48160 Derio
Bizkaia - Spain

+34 94 656 7900
info@histocell.com

Histocell Factory

Polígono Sasine. Patakon s/n
48195 Larrabetzu
Bizkaia - Spain

+34 94 656 7900
info@histocell.com

Our mision

We develop new advanced therapy medicinal products, medical devices and dermocosmetics to improve people's quality of life.

Copyright © Histocell